To get the free app, enter your mobile phone number.
Successful Biotech Investing: Every Investor's Complete Guide Hardcover – May 24, 2001
The Amazon Book Review
Author interviews, book reviews, editors picks, and more. Read it now
Customers Who Bought This Item Also Bought
Top Customer Reviews
The book gives you a basic scientific background of the biotechnology industry, describes the way that the industry is regulated in creating new drugs, profiles the leading pharmaceutical and biotechnology companies, proposes a way to evaluate the fundamental performance of each company, and describes the ways that you can use technical analysis to pick when to buy and sell these stocks.
This helpful information is provided against the context of the wild swings in stock prices as the overall market and general news move stock price levels. He begins by pointing out that the statement by President Clinton and Prime Minister Blair that the rights of biotechnology companies should be restricted was a short-term storm, but a long-term non-event. Such moments provide buying opportunities.
The book has two basic weaknesses. First, it fails to point out that most people should avoid biotechnology stocks. They should be very volatile, and can have stomach-churning drops that will cause many investors to sell at the worst times. The vast majority of ordinary investors should be buying broad-based index funds (see Common Sense on Mutual Funds). Second, the book fails to point out that the rate of discoveries in any given company should be slowing down in the future. This is because after a company is public, it will usually limit R & D to try to create a profit track record and because the science is simply more difficult and lengthy as more proteins and enzymes become involved in solutions. As a result, we could see very long time periods when investments will be under water.Read more ›
Most investors invest in biotech stocks based on media exposure and momentum driven markets. There is a glaring lack of any sort of structure to their research or position management. Dr. Duarte's book lays the groundwork for investors to establish a workable system of identifying and managing promising investments. By incorporating risk management techniques (technical analysis), he has provided a dose of reality to balance the inherent optimism the motivates biotech investors. This is crucial as it prevents the blow ups that destroy portfolios as well as investor confidence.
Most Recent Customer Reviews
The book looks great, but it is definitely not worth reading. If you are into technical analysis, you may derive some use from the text. Read morePublished on May 16, 2004
Since I'm not interested in being a PhD this seems like the perfect book for me and more than likely for the average investor. Read morePublished on June 15, 2001
Dr. Duarte has put it all together in this book. The future of biotech stocks is incredible, but investing without a full understanding of the industry is risky. Read morePublished on June 13, 2001 by Frank Kollar